Insight Molecular Diagnostics
IMDX
58 hedge funds and large institutions have $19.6M invested in Insight Molecular Diagnostics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 13 closing their positions.
0.23% less ownership
Funds ownership: 2.79% → 2.56% (-0.23%)
11% less funds holding
Funds holding: 65 → 58 (-7)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
47% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 19
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
60% less capital invested
Capital invested by funds: $48.4M → $19.6M (-$28.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.2K |
| 2 |
TLP
Tri Locum Partners
New York
|
+$21.4K |
| 3 |
E
Ergoteles
New York
|
+$21.2K |
| 4 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
+$17.6K |
| 5 |
Renaissance Technologies
New York
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.37M |
| 2 |
BlackRock
New York
|
-$489K |
| 3 |
AIC
AWM Investment Company
New York
|
-$271K |
| 4 |
PM
Penbrook Management
New York
|
-$196K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$180K |
IMDX Hedge Fund Activity: Q4 2022 in Review
58 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2022, worth a combined $19.6M — down 60% from $48.4M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IMDX and 8 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 10 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $36.2K. The largest seller was OrbiMed, exiting entirely with an estimated $1.37M sold.
- 58 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2022, down from 65 in Q3 2022.
- Funds reported $19.6M of Insight Molecular Diagnostics stock for Q4 2022, down 60% quarter-over-quarter.
- 8 funds opened new Insight Molecular Diagnostics positions in Q4 2022 and 13 closed out, a net change of -5 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2022 was Susquehanna International Group, an estimated $36.2K added.
- The largest Insight Molecular Diagnostics seller in Q4 2022 was OrbiMed, an estimated $1.37M sold.
Based on aggregated 13F filings for Q4 2022.